Abortion drug could help reduce risk of breast cancer, group of medics says
However, 'stigma' around mifepristone is stopping pharmaceutical companies from investigating its potential as a new treatment doctors could offer to reduce the risk of breast cancer, they say.
Companies appear reluctant to carry out trials despite the fact that three previous studies all found that the drug shows promise as a way of slowing down the growth of cancerous cells.
Mifepristone's role in medical abortions and fact that access to abortion is restricted in some countries is preventing much-needed research being done, the experts claim.
It is one of two drugs, alongside misoprostol, that women in the UK take when ending a pregnancy that began up to 10 weeks earlier. They take a mifepristone tablet, then wait for 24-48 hours and then take the misoprostol.
'It is deeply disappointing that the successful application of mifepristone in one area of clinical medicine is hindering more extensive research into other indications that could benefit public health,' the opinion piece written by eight co-authors and published in The Lancet Obstetrics, Gynaecology and Women's Health says. All are experts in reproductive health or reproductive cancer working in London, Edinburgh, Stockholm and Erbil in Iraq.
'The time is long overdue to give mifepristone the opportunity it deserves to be investigated as a non-surgical option for primary prevention [of breast cancer],' they add.
Breast cancer is the most common female cancer in most countries in the world and kills an estimated 670,000 women globally every year, according to the World Health Organization.
Although small-scale, the three previous studies offered evidence mifepristone can limit the effect of the hormone progesterone, which drives the cell growth found in breast cancer. They were published in 2008, 2022 and 2024.
Mifepristone is a type of drug known as a selective progesterone receptor modulator.
If proven to work, it could help women who are at high risk of breast cancer, such as those who carry a variant of the BRCA1 or BRCA2 genes. Currently they are offered surgical options for their treatment, such as a mastectomy, or drugs that are of 'low efficacy', the authors say.
UK cancer charities endorsed the plea for drug companies to look seriously into the role mifepristone could play in breast cancer care and for governments to enable that to happen by easing regulations that restrict its use to abortion.
Dr Simon Vincent, the chief scientific officer at Breast Cancer Now, said: 'More risk-reducing treatment options for women with a high risk of developing breast cancer, that also protects their quality of life, are desperately needed. And we need to explore all avenues, including existing drugs, to achieve this.
'So early research into mifepristone is an important step forward and we need further studies to understand if these drugs are safe and effective.'
Dr Marianne Baker, Cancer Research UK's science engagement manager, said the 57,900 new diagnoses a year of breast cancer in Britain showed that 'it's vital we invest in research exploring new ways to prevent the disease'.
She added: 'Cancer develops when cells grow uncontrollably. Early studies showed that mifepristone slowed down cell growth in breast tissue, so it might be useful in delaying or preventing cancer.
'But we need more research to understand whether it's effective, how it works and who would benefit most from it.'
Prof Kristina Gemzell Danielsson, the piece's lead author, and who heads the department of women's and children's health at the Karolinska Institute in Stockholm, said: 'Stigma around mifepristone used for abortion is describing part of why mifepristone is not more extensively researched for prevention of breast cancer.
'Taken together, our data support the use of mifepristone for prevention of poor prognosis breast cancer. All studies were randomised controlled trials using a low dose of mifepristone for two or three months.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
24 minutes ago
- Daily Mail
Shocking discovery reveals millions are living with undiagnosed neurological disorder
Many girls face years-long delays in receiving autism diagnoses, with many not diagnosed until adulthood, new research has shown. Diagnosing autism - which impacts more than 5million adults and over 2million children in the US - can be difficult because there is no definitive medical test, such as blood draws or MRI scans, to diagnose the disorder. Doctors instead must look at the child or adult's developmental history and behavior to make a diagnosis. In the recent study by Epic Research, researchers reviewed records from more than 338,000 patients who received their first autism spectrum disorder diagnosis between 2015 and 2024. They found that the median age at autism diagnosis declined slightly from seven years of age in 2015 to six years in 2024, thanks to improved understanding of the condition. However, they discovered that male patients are increasingly diagnosed earlier with the median age at diagnosis dropping from seven years in 2015 to five in 2024. This contrasts with the trend for females, with the median age of diagnosis remaining around the age of eight over the same period. Digging into the data further, the researchers discovered among male patients diagnosed with autism in 2024, 44 percent were under age five, compared to 34 percent for females. They said that this indicated that more than half of these female patients were diagnosed later than age five and 'might have benefitted from earlier diagnosis'. They also found that the proportion of female patients diagnosed as adults (aged 19 plus) was 25 percent in 2024, while 12 percent of males were diagnosed with autism as adults in the same year. Dr Brian Harris, a behavioral health and development physician at Orlando Health who was not involved in the study, says the diagnosis gap between girls and boys is largely due to the traditional diagnosis model. Offering an explanation as to why the gap exists, he says: 'Despite the benefits of early diagnosis and intervention, most autistic children are not diagnosed until they begin school, by which time they and their peers are expressing rigid gender-based stereotypes. 'That may be why the behavior of a loud and rowdy autistic boy catches attention while that of a quiet girl expressing subtler symptoms may not. 'In other words, the model we've been using to diagnose ASD is a male model, but we are changing that. 'Specialists at all levels are being trained to recognize symptoms in boys and girls because a diagnosis provides clarity, enhances understanding, and opens access to support, resources and services that can be life-changing.' Early research from the 1960s and 1970s estimated autism affected just two to four out of every 10,000 children, but the condition was poorly understood at the time. While diagnosis rates have steadily climbed over the years, they were already much higher by 2000, when the CDC reported a prevalence of 1 in 150 children aged eight or younger. This then jumped to one in 44 in 2018, one in 36 in 2020, and one in every 31 children in 2022 - a rate of 32.2 per 1,000. By comparison, early studies from the 1960s and 1970s estimated autism rates to be as low as 1 in 5,000. The most recent CDC report found wide geographic variation, with diagnosis rates ranging from roughly one in 100 in parts of south Texas to a striking one in 19 in San Diego. It also highlighted shifting demographic patterns: autism diagnoses were more frequent among Asian, Black, and Hispanic children than among White children — a trend first observed in the 2020 data. Researchers say the sharp rise in recent decades can be partially explained by improved screening, increased public awareness, and better access to services. While some blame an ultra-processed diet, chemicals and pesticides for the rise. The average age for an autism diagnoses is five, though the vast majority of parents notice differences in their children, particularly around social skills, as early as two years old. Looking ahead, Professor Rinehart says more research needs to be done to better understand the autistic gait. This will be particularly beneficial to children so that treatment plans can be tailored for their individual movement styles as they develop.
The Guardian
an hour ago
- The Guardian
Booze up: is gen-Z's ‘sensible' relationship with alcohol moving towards hedonism?
Gen-Z have long been hailed as 'generation sensible' – dozens of articles have charted how they drink less alcohol, exercise more, eat healthier and have ditched night clubs for book clubs. But could that be about to change? Recent data has shown the proportion of gen Z – those born roughly between 1997 and 2012 – who are of legal drinking age and have consumed alcohol in the past six months has risen by 7% between 2024 and 2025. Alcopops are apparently all the rage among gen-Z customers, with booming sales of Smirnoff Ice, Bacardi Breezers and BuzzBallz, while last year's 'brat summer' was said to herald the end of the clean living era. The reality, experts say, is more complicated than that. 'We're seeing a generational recalibration, not a simple return to hedonism,' said Ivo Vlaev, a professor of behavioural science at Warwick University. 'This isn't a simple return to the past – it's a complex blend of coping, compensation, identity expression and socioeconomic constraint. The behaviours may look familiar, but the psychology behind them has evolved.' He said the fact that gen-Z came of age during a pandemic, climate crisis and increased concerns over the cost of living was a recipe for 'psychological whiplash'. Key factors at play included a rebound from the restrictions of the Covid era with young people now 'reasserting agency through social behaviours'. Vlaev said research showed that 'when autonomy is suppressed, people later overcompensate with behaviours that signal freedom or control'. There was also an element of 'self-soothing' as a result of rising levels of anxiety, depression and loneliness, as well as the glamorisation of certain drinks and behaviours on TikTok. Financial concerns may have also pushed the younger generation towards 'present-biased decision-making'. 'When the future feels unstable, people are less likely to invest in long-term health and more likely to seek short-term mood boosts, like alcohol or late nights out,' he said. Vlaev also said an element of 'wellness culture' fatigue had probably set in. 'Some gen-Zers are pushing back against the pressure to optimise every aspect of life,' he said. Richard Halstead, chief operation officer of consumer research at drinks market analysis company IWSR, said: 'From a consumer research and data point of view, it does seem there is some pushback on this idea that we're all perfect, having perfect pictures taken of us on Instagram and we're all super in control of our lives. 'Every cultural move has a countercultural move associated with it.' He said gen Z's attitudes towards drinking and socialising was more nuanced than is often portrayed in the media – gen Z were not 'puritans' who abstain from alcohol, but nor did they like booze as much as previous generations. 'The idea that gen Z do not drink at all or that they have turned their backs on alcohol is not supported by data,' he said. 'The idea that they have a different relationship with alcohol compared to previous generations is supported by data.' He said that, for instance, gen-Z were more likely to drink a wider variety of alcohols, and drink out in bars and restaurants. 'Their pattern of behaviour is actually going out for a reason, as opposed to just meeting for a pint in the pub because the pub's there and you've got nothing better to do,' he said. Dr Laura Tinner, a research fellow at the Centre for Public Health at the University of Bristol, said people shouldn't underestimate the power of the alcohol companies themselves, keen to capture a younger audience they feared they were losing. 'It's not necessarily that there has been a swing in the pendulum or a return to previous drinking behaviours, it's more that alcohol companies are continually trying to target young people with their products,' she said. 'They are using the current revival and zeitgeist around 00s and 90s culture to design their products to target young people.' There was also a suggestion that gen-Z were simply older – they are now roughly between the ages of 13 and 28 – so those at the older end of the group were more likely to have access to well paid jobs and disposable income. 'I think we're seeing some tailwinds develop,' said Halstead. 'They're getting older so some are probably in better paying, stable jobs and they've got more opportunity perhaps to do things that people with a bit more money like to do, which is go out and buy a drink and not worry too much about how much it costs you.' What many researchers were interested in was whether the characteristics that make gen Z different from their predecessors will stay with them as they age, with evidence suggesting generations become more and more similar as they get older. 'We've always had a question about whether or not the decline [in drinking alcohol] will persist into adulthood,' said Dr Laura Fenton, a research associate at the University of Sheffield who specialises in youth drinking cultures. 'What makes gen-Z slightly distinct as a generation is their attitude towards risk. They've engaged in fewer [risky pursuits] proportionally compared to people their age 20 years ago – and that extends to sex, it extends to driving, it extends to smoking and drug use,' she said. 'I think the question really is, is their approach to risk going to stay intact?'
The Guardian
an hour ago
- The Guardian
Exposure to some common Pfas changes gene activity, new study finds
New research suggests exposure to some common Pfas or 'forever chemical' compounds causes changes to gene activity, and those changes are linked to health problems including multiple cancers, neurological disorders and autoimmune disease. The findings are a major step toward determining the mechanism by which the chemicals cause disease and could help doctors identify, detect and treat health problems for those exposed to Pfas before the issues advance. The research may also point toward other diseases potentially caused by Pfas that have not yet been identified, the authors said. The study is among the first to examine how Pfas chemicals impact gene activity, called epigenetics. 'This gives us a hint as to which genes and which Pfas might be important,' said Melissa Furlong, a University of Arizona College of Public Health Pfas researcher and study lead author. Pfas are a class of about 15,000 compounds most frequently used to make products water-, stain- and grease-resistant. They have been linked to cancer, birth defects, decreased immunity, high cholesterol, kidney disease and a range of other serious health problems. They are dubbed 'forever chemicals' because they do not naturally break down in the environment The study checked the blood of about 300 firefighters from four departments across the country who were exposed to high levels of Pfas. The chemicals are the main ingredient in most firefighting foam, and are frequently used in 'turnout gear' worn by firefighters because of their heat repelling properties Furlong said she was surprised to find the number of genes and biological pathways that were impacted by Pfas, which suggests the chemicals may cause or contribute to a broad range of health problems. The study did not prove the chemicals cause certain diseases, but findings point to biological changes that might precede disease. Genes play a range of roles in developing or preventing disease, and Pfas essentially change the way the genes are supposed to act, Furlong said. A gene may act as tumor suppressor, but the Pfas interferes with how it expresses, which affects whether cancer develops, or the type of cancer. For example, PFOS, among the most common and dangerous Pfas compounds, reduces levels of miR-128-1-5p, a gene tied to cancer development. Branched forms of PFOS were linked to changes in five other genes, including some that regulate cancer development. Sign up to Detox Your Kitchen A seven-week expert course to help you avoid chemicals in your food and groceries. after newsletter promotion Different Pfas and chemical structures were found to affect different genes, and were associated with different health outcomes. Not all compounds impacted gene expressions. The research found connections among Pfas-related gene changes and biological pathways involved in leukemia, as well as bladder, liver, thyroid and breast cancers. Other genes and biological pathways were involved in Alzheimer's disease, and autoimmune and infectious diseases such as lupus, asthma and tuberculosis. Furlong said it remains unclear at which step in the biological processes disease is triggered, but the picture is clear enough to point to possible treatments. Pharmaceutical companies are trying to develop drugs that could alter gene activity and potentially prevent Pfas-linked disease from developing.
